Indicating an anti-proliferative effect via cell cycle inhibition, resminostat treatment of HCC cells led to accumulation of the cell cycle inhibitor p21 protein (cyclin-dependent kinase inhibitor 1), an established HDAC target (Fig. S1C)25,26. This evidence concerns the gene CDKN1A and hepatocellular carcinoma.